Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
Published: Jul 06, 2023
Vaxart, Inc. (Nasdaq: VXRT) today announced positive topline data from the dose-ranging Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate.
The preliminary results of the trial showed robust serum immune responses across all doses at Day 29 relative to Day 1. Both doses exhibited a similar increase in serum antibody responses with no statistical difference between the medium and high dose arms. The increases in serum IgA, IgG, and BT50 for both the GII.4 and GI.1 strains were similar to previous studies conducted by Vaxart. Mucosal and cell-based assay data will be available later.
This is reference article: Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2